Evaluation of the Efficacy of Dasatinib, a SRC/Abl Inhibitor, in Colorectal Cancer Cell Lines and Explant Mouse Model

PLoS ONE - United States
doi 10.1371/journal.pone.0187173
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Scalable and Impurity-Free Process for Dasatinib: SRC and BCR-Abl Inhibitor

Asian Journal of Chemistry
Chemistry
2018English

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, Against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation

Clinical Cancer Research
Cancer ResearchOncology
2008English

Evaluation of Colorectal Cancer Subtypes and Cell Lines Using Deep Learning

Life Science Alliance
Plant ScienceEcologyGeneticsMolecular BiologyBiochemistryMutagenesisHealthToxicology
2019English

Second-Generation SRC/Abl Inhibitor Bosutinib Effectively Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma (ESCC) Cells via Inhibiting SRC/Abl Signaling

Neoplasma
Cancer Research
2020English

Identification and Evaluation of a Potent Novel ATR Inhibitor, NU6027, in Breast and Ovarian Cancer Cell Lines

British Journal of Cancer
Cancer ResearchOncology
2011English

Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model

PLoS ONE
Multidisciplinary
2013English

In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells

Cancer Research
Cancer ResearchOncology
2006English

Mitochondrial DNA Alterations in Colorectal Cancer Cell Lines

Journal of Nippon Medical School
Medicine
2011English

Antitumor Activities of JTP-74057 (GSK1120212), a Novel MEK1/2 Inhibitor, on Colorectal Cancer Cell Lines in Vitro and in Vivo

International Journal of Oncology
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy